Medtronic : strengthens its extensive body of real-world evidence on its MiniMed™ 780G system with new presentations at the American Diabetes Association 84th Scientific Sessions

Medtronic, a global leader in medical technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) 84th Scientific Sessions. Following the one-year anniversary of the MiniMed™ 780G system approval and launch in the U.S., Medtronic Diabetes continues to demonstrate its success with consistently strong real-world evidence - particularly around its unique ability to manage hyperglycemia across diverse populations of individuals with type 1 diabetes. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.